# OnCo record captain-1st (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/captain-1st/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "captain-1st", "NCT03707509" ;
  schema:name "CAPTAIN-1st"@en ;
  schema:description "CAPTAIN-1st showed that adding the PD-1 antibody camrelizumab to gemcitabine and cisplatin kept advanced nasopharyngeal cancer under control for about three months longer, confirming with a second drug what JUPITER-02 found with toripalimab."@en ;
  schema:url <https://onco.cc/trials/captain-1st/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03707509> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:institutions <https://onco.cc/institutions/sysucc/> ;
  onco:trials <https://onco.cc/trials/jupiter-02/> .